Treatment of Histologic Transformation

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Histologic transformation from follicular lymphoma (FL) to aggressive lymphoma historically carried a poor prognosis.
• The introduction of anti-CD20 antibody rituximab has significantly improved outcomes for select FL patients.
• Understanding the risk factors and biology of transformation is crucial for patient management.

Purpose of the Study:

• To review the current understanding of risk factors associated with FL transformation.
• To provide an overview of the prognosis for patients experiencing histologic transformation.
• To summarize the treatment strategies for transformed FL.

Main Methods:

• This review synthesizes existing literature on follicular lymphoma transformation.
• It examines clinical and biological biomarkers predictive of transformation.
• The review discusses treatment outcomes in the era of rituximab therapy.

Main Results:

• Rituximab therapy has improved outcomes for transformed FL, approaching those of de-novo diffuse large B-cell lymphoma in some cases.
• Several biomarkers have been identified that can predict the risk of transformation.
• Research continues to elucidate the biological mechanisms underlying transformation.

Conclusions:

• Histologic transformation of FL is a critical event, but prognosis is improving with modern therapies like rituximab.
• Identifying patients at high risk for transformation through biomarkers is essential for proactive management.
• Further research into the biology of transformation will likely lead to even better therapeutic strategies.